Fraunhofer Institute for Cell Therapy and Immunology IZI

Making novel therapeutics safer

Press Release | December 2, 2019

more info

Periodontal disease: Patent for new treatment method

Press release of the Martin-Luther-University Halle-Wittenberg | November 25, 2019

more info

REANIMA: toward a new paradigm in cardiac regeneration

Press Release | November 7, 2019

more info

One year on: Kymriah® CAR-T cell therapy in Germany

Press Release Novartis | October 7, 2019

more info

We transfer biomedical research into the clinic.

The Fraunhofer Institute for Cell Therapy and Immunology IZI investigates and develops solutions to specific problems at the interfaces of medicine, life sciences and engineering. One of the institute‘s main tasks is to conduct contract research for companies, hospitals, diagnostic laboratories and research institutes operating in the field of biotechnology, pharma­ceuticals and medical engineering.

The Fraunhofer IZI develops, optimizes and validates methods, materials and products for the business units Cell and Gene Therapy, Drugs and Diagnostics. Its areas of competence lie in cell biology, immunology, drug biochemistry, bioanalytics and bioproduction as well as process development and automation. In these areas, research specifically focusses on the indications oncology, immunological diseases as well as infectious diseases and neurodegenerative diseases.

The institute works in close cooperation with hospital institutions and performs quality tests besides carrying out the GMP-compliant manufacture of clinical test samples. Furthermore, it helps partners obtain manufacturing licenses and permits.

Business units

Jobs / career

Press

Publications

Research projects funded by the EU

News

 

Press Release / 3.12.2019

Making novel therapeutics safer

Fraunhofer IZI takes lead on EU project developing highly innovative model systems to evaluate immunomodulatory therapeutic agents. The development of immunomodulatory agents and therapies has received fresh impetus following the latest successes in immuno-oncology. And cancer medicine is not the only area where cell and gene therapies are increasingly taking hold ...

 

Press release of the Martin-Luther-University Halle-Wittenberg / 25.11.2019

Periodontal disease: Patent for new treatment method

New biodegradable rods promise to provide better treatment for periodontal disease. Researchers from the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have re-combined an already approved active ingredient and filed for a patent for their invention together with two Fraunhofer Institutes from Halle. The innovation would spare patients from having many side effects. Their findings were published in the "International Journal of Pharmaceutics".

 

Press information / 7.11.2019

REANIMA: toward a new paradigm in cardiac regeneration

Research into new endogenous mechanisms of tissue regeneration is an innovative research avenue in cardiac regeneration. This is the central goal of the REANIMA project (New‐generation cardiac therapeutic strategies directed to the activation of endogenous regenerative mechanisms) ...

Press information Novartis / 7.10.2019

One year on: Kymriah® CAR-T cell therapy in Germany

  • Around one year ago, the European Commission approved the use of Novartis’ CAR-T cells in Germany for patients diagnosed with certain types of life-threatening blood cancer who have extremely limited survival prospects.
  • Each patient-specific CAR-T cell infusion is the result of an individualized, innovative manufacturing and logistics process that Novartis has established together with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig.
  • In Germany, more than 15 hospitals1 are now certified to carry out the CAR-T cell therapy developed by Novartis.

Contact

Fraunhofer IZI

 

Perlickstraße 1
04103 Leipzig
Germany

Phone +49 341 35536-1000
Fax +49 341 35536-8-1000
E-mail info@izi.fraunhofer.de

 

Social Media